Clinical Trials Using Denosumab
Clinical trials are research studies that involve people. The clinical trials on this list are studying Denosumab. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Denosumab in Treating Patients with Multiple Myeloma with Kidney Insufficiency
This phase II trial studies how well denosumab works in treating patients with multiple myeloma with kidney insufficiency. Immunotherapy with monoclonal antibodies, such as denosumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread
Location: 8 locations
Denosumab and Pembrolizumab or Nivolumab in Treating Patients with Stage III-IV Cutaneous or Mucosal Melanoma
This phase II trial studies the side effects of denosumab and pembrolizumab or nivolumab and to see how well they work in treating patients with stage III-IV cutaneous or mucosal melanoma. Immunotherapy with monoclonal antibodies, such as denosumab, pembrolizumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Denosumab in Treating Patients with ER and / or PR Positive, HER2 Negative Metastatic Breast Cancer with Bone Metastases and Detectable Circulating Tumor Cells
The purpose of this study is to look at the amount of cancer cells in the blood of participants who are being treated with denosumab. The other purpose is to look at how long it takes for cancer to get worse when participants are being treated with denosumab. Circulating tumor cells (CTCs) in the blood of patients with metastatic breast cancer (MBC) have been associated with shorter survival than when CTCs are absent, especially in patients whose cancer has spread to their bones. In this study, we want it see if denosumab (the study drug) will decrease the number of CTCs measured in patients with MBC and cancer that has spread to their bones. We also plan to get blood from participants to study other research markers of interest.
Location: Northwestern University, Chicago, Illinois
Denosumab in Treating Patients with Bone Loss due to Donor Stem Cell Transplant
This phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant. Patients receiving a donor stem cell transplant may experience accelerated bone loss and an increase risk of bone fractures, leading to a decrease in satisfaction and quality of life. A type of immunotherapy drug called denosumab binds to a protein called RANKL, which may help keep bone from breaking down.
Location: 2 locations
Pilot Study of Denosumab in BRCA1 / 2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
This randomized pilot early phase I trial studies how well denosumab works in BRCA1 / 2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy. Denosumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Location: 4 locations
Denosumab for Decreasing Breast Density in High Risk Premenopausal Women with Dense Breasts
This phase II trial studies how well denosumab works in decreasing breast density in premenopausal women with dense breasts who have a high risk of developing breast cancer. Having dense breasts is associated with an increased risk of developing breast cancer, therefore reducing breast density may decrease this risk. Denosumab is a monoclonal antibody that may reduce breast density by blocking progesterone associated cell growth in breast tissue.
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Response of Bone Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers with Actionable Driver Mutations
This trial studies the response of bone metastasis to tyrosine kinase inhibitors in non-small cell lung cancers with actionable driver mutations. This study plans to learn more about how different drug regimens for advanced non-small cell lung cancer and bone metastases affect bone turnover markers and the need for additional drugs to treat bone metastases.
Location: University of Colorado Hospital, Aurora, Colorado